The future of early-phase trials is being built right now—and this issue takes you straight to where it’s happening. From global regulatory overhauls to first-in-human breakthroughs, you'll get sharp insights designed to inform your next strategic move.
first-in-human · clinical trial · regulatory
The future of early-phase trials is being built right now—and this issue takes you straight to where it’s happening. From global regulatory overhauls to first-in-human breakthroughs, you’ll get sharp insights designed to inform your next strategic move.
Your next trial decision starts with what’s happening now—let’s get into it.
Most 510(k) submissions don’t make it through the first time — but they can. The difference? Smart strategy, not just solid science.
Getting it right means more than just ticking regulatory boxes. It’s about choosing the right predicate device, building a clinical strategy that matches FDA expectations, and preparing your submission in the new eSTAR format — now non-negotiable. When these pieces align, clearance can drop from 6–12 months to just 6–8 weeks.
For Medtech teams planning first-in-human, early feasibility, or pilot studies in Latin America, Latin America, or Australia, this is how regulatory and clinical design come together to fast-track entry into the U.S. market.
Brazil has officially launched a fully digital certificate issuance tool, replacing the aging Sicert system. Now integrated with ANVISA’s Solicita platform, the new system offers real-time previews, multilingual templates, and QR-code validation to streamline the certification process.
This shift supports a faster, more transparent regulatory pathway for Medtech sponsors — especially those preparing for early-phase studies in Latin America. The Sicert system will be deactivated on December 1, 2025, and all certificate issuance will move to the updated platform.
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule Your First-in-Human Trial Consult.
In a global first, a CRISPR-based gene editing therapy has been shown to safely lower cholesterol and triglyceride levels in humans. The one-time treatment silenced the ANGPTL3 gene, which plays a key role in lipid metabolism, offering a potential breakthrough for patients with familial hypercholesterolemia and other hard-to-treat cardiovascular conditions.
The trial was conducted in New Zealand and Australia, positioning the region as a rising hub for early-phase gene therapy research and first-in-human trials. No serious safety events were reported, and all participants experienced meaningful lipid reductions after just one dose.
Why this matters:
Mexico is reimagining its healthcare system—not through sweeping reform, but through cross-sector collaboration that’s steadily replacing fragmentation with innovation. Public health networks, private clinics, startups, and universities are beginning to align around shared goals, creating new spaces for digital health, interoperability, and medical education.
What makes this shift unique is Mexico’s flexibility. With fewer rigid bureaucracies, it’s becoming a real-world lab for experimentation: from telemedicine platforms and EHR systems to ethics-based data sharing models and trusted physician networks. Early momentum is visible in metrics like 28% growth in medical device authorizations and a digital health market projected to triple by 2030.
As clinical trials move toward more inclusive frameworks, trial sponsors and regulators are rethinking how protocols account for gender, pregnancy status, and social representation. While policy guidance exists, execution still varies widely, and the risks of under-representation continue to impact data quality and outcomes.
Key takeaways:
A new brain monitoring device has received De Novo classification from the FDA. Using EEG and transcranial magnetic stimulation, it measures real-time brain responses to detect early signs of neurological conditions like dementia and stroke. Already CE-marked and in use at major U.S. institutions, it’s gaining attention for its potential role in trial settings.
This classification highlights how non-invasive, intelligent diagnostics are becoming essential tools in early-phase trials—especially those requiring fast, objective neurological endpoints.
← All Global Trial Accelerators editions · Contact bioaccess®